Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MKC253 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 1.5 mg dose of GLP-1 as MKC253 Inhalation Powder |
| 2 | EXPERIMENTAL | 1.5 mg dose of GLP-1 as MKC253 Inhalation Powder |
| 3 | EXPERIMENTAL | 1.5 mg dose of GLP-1 as MKC253 Inhalation Powder |
| 4 | PLACEBO_COMPARATOR | TIP (placebo comparison) |
| 5 | ACTIVE_COMPARATOR | 10 ug subcutaneous control |
| Name | Type | Description |
|---|---|---|
| MKC253 Inhalation Powder | DRUG | Inhalation Powder, prandial |
| Technosphere Inhalation Powder | DRUG | Inhalation Powder, prandial |
| subcutaneous injection | DRUG | 10µg Exenatide, prandial |
Inclusion Criteria: * Non-smoking males and females between 18 and 70 years of age * Body Mass Index (BMI) of \< 32 kg/m2 * Diabetes managed on a stable regimen of diet and exercise within the preceding 8 weeks and/or metformin and/or a sulfonylurea or meglitinide or alpha glucosidase inhibitors, w...
MKC253 is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It is administered as an inhalation powder and is currently in Phase 1 clinical development. The drug is being studied for its safety, tolerability, and pharmacological response in adults with Type 2 diabetes.
MKC253 is being developed by MannKind Corporation, a biopharmaceutical company traded on NASDAQ under the ticker MNKD. The company is conducting clinical trials to evaluate the safety and pharmacological response of this inhaled small molecule in patients with Type 2 Diabetes Mellitus.
MKC253 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 46 participants enrolled. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of Type 2 Diabetes Mellitus.
MKC253 has been studied in two completed Phase 1 clinical trials. NCT00475371 evaluated single-dose safety and tolerability in healthy adult males, enrolling 26 participants. NCT00642538 assessed safety and pharmacological response in adults with Type 2 Diabetes Mellitus, enrolling 20 participants. Both trials were conducted in the Netherlands.
MKC253 is administered as an inhalation powder. This route of delivery is being studied in clinical trials for the treatment of Type 2 Diabetes Mellitus. The drug is a small molecule and is currently in Phase 1 development, with completed trials evaluating its safety and tolerability in healthy volunteers and adults with diabetes.